Abstract 50P
Background
The management of bone sarcoma has too many challenges in the management of patients with Bone Sarcoma in the region. This study was undertaken to underscore these difficulties and pave the way for improvements in patient management. Identifying and addressing these challenges will contribute to enhancing the overall quality of care for individuals with Bone Sarcoma specially with recent inauguration of the University Hospital of Tangier. Aim of study:To identify and address the shortcomings in the management of bone sarcomas, thereby improving the quality of care.
Methods
This is a retrospective study that included patients diagnosed with STS at the Medical Oncology Department of the university hospital in Tangier between December 2019 and November 2023. Data were collected from medical records using a pre-established sheet form. Statistical analysis was conducted using SPSS.
Results
The study included 44 patients, with a median age of 26 years and 61% being males. Most patients had no personal medical history. The femur was the most common localization (32%). Ewing sarcoma accounted for 47.7%, while osteosarcoma comprised 52.3% (conventional osteosarcoma in 45% of the cases). Immunohistochemistry was performed in 52% of patients, molecular biology in 26% of patients with Ewing sarcoma (It was requested but not done), and histopathological review in only 28%. Staging procedures included MRI and chest CT for almost all patients, bone scintigraphy for 22%, and bone marrow biopsy for 9%. At diagnosis, 70.5% of patients had a local or locally advanced stage, and 29.5% were metastatic. Multidisciplinary team reviews occurred in 13.6% at diagnosis and 27.3% during management. Surgery was performed in 36.4%, exclusively at the university hospital, while radiotherapy was administered in 29.5% (57% palliative). Chemotherapy was given to 100% of metastatic patients and 65% of locally staged patients. The median survival was 36 months.
Conclusions
This study highlights challenges, especially regarding the anatomopathology diagnosis, the review process and molecular biology. There are also challenges related to the availability of extension assessments. In the hope that with the efforts made by the team of the department, we will achieve better results in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Amzerin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.